Artificial Intelligence Diagnostic Aid

NCT ID: NCT05675540

Last Updated: 2023-05-18

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 422 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-06-01
• Study Completion Date: 2024-03-30

Brief Summary

The investigators have worked with software designers to develop a software that allows us to analyse current adherence to guidelines on Ophthalmic conditions such as Age related Macular Degeneration (AMD), Diabetic Macular Edema (DMO) and Retinal vein occlusion (RVO). National guidelines state that those patients with fluid accumulation in their central macular, meeting criteria, are eligible for injections into the vitreous cavity of the eye (intravitreal).(1) As these condition are common the trial is relevant to the public and patients as future management may be affected by the outcomes of this trial. The investigators will trial the software which uses Artificial Intelligence (AI) algorithms to determine the most suitable review required for patients being managed in clinics, based on 'Vision' and 'Retinal Thickness' demographics. This will be done prospectively, in real time.

The question to be addressed is 'Can medical and non-medical practitioners accurately determine treatment and follow-up for patients assisted by an AI clinical decision support system, for the three most common chronic macular diseases - Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) and Retinal Vein Occlusion (RVO) - in a safe and clinically cost effective way?' Patients undergoing treatment for at least 12 months are eligible to participate, so long as they are able to provide consent for their data to be used. Participants will have no change to their care during the trial. The study, will take place at Guy's and St. Thomas' NHS FT (GSTT) from where participants will be recruited, and will last approximately 6 months of data collection.

The software will be used by the research Fellow, alongside the masked consultant. Therefore the patient pathway and management will not be impacted by this trial. Patients will be consented for data use.

Detailed Description

Gulliksen (2017) describes digitalization as the biggest societal transformation process, including for the health-care sector. Since the challenges of the pandemic, digitalization has particularly taken place during changes to how healthcare is provided. The current Global Healthcare situation dictates flexible and innovative steps to practically adapt working methods in clinic to meet the demands of specialities, such as Ophthalmology, in safe and efficient ways. Macular disease causes devastating sight loss. It is the most common cause of preventable sight loss in the UK and the developed world, leading to unnecessary and debilitating loss of vision and blindness if not monitored and treated regularly. In the UK, 1.8M people have chronic macular disease, of which approximately 300,000 reside in London. Allied health professionals are trained to give the injections but at the moment there is no formal structure for AHPs to be trained to assess patients data (vision and OCT scan).

The investigators therefore suggest it is an important area of research, to develop a management aid to allow standardization of care, and allow more patients to be seen by increasing the clinical workforce. This new AI software enables the mobilization of the broader non-medical workforce of over 14,000 optometrists as well as nurses, allied health professionals and technicians who can be up-skilled with AI tools and training, and operate from community settings to expand resources, capacity and the quality of care. Whilst the algorithm is not aimed to improve knowledge of the diseases, there will be an element of learning of good management by the end user. There are currently many examples of automated software in literature, however they all end at the validation stage. They all address the use of AI to diagnose conditions, but none have addressed the issue of implementation, as highlighted by many of the papers. There are also no trails aimed at the management of these patients, subsequent to diagnosis.

This study will compare gold standard clinical care of patients receiving treatment for the three main macular diseases (treatment decisions made by an ophthalmologist) with an assessment and treatment recommendation made by the MacuSense software. The patients' treatment will follow the ophthalmologists decision at all times, and the result of the study will compare this with the MacuSense output. The ophthalmologist will be blind to the MacuSense output throughout the study.

The research participant will attend their clinic appointment, with measures of vision and a retinal (OCT) scan as normal. The ophthalmologist will review the patient and scan with a treatment and follow up interval decided. Treatment will be given at that visit.

The data collected will be entered into the MacuSense software by the principal investigator (Dr Zakri). The output of the software gives a follow up interval. The result of the follow up interval decided by the clinician and the follow up interval indicated by the Macusense software will be compared for each patient. The ophthalmologist will not have access to Macusense software or the output of the software, so that their treatment decision is not affected. The output of the Macusense software will not be used to change the clinical decision.

The output of the study is therefore to compare the clinician treatment and follow decision with the Macusense result, for research purposes only. The aim is to test the accuracy of the Macusense algorithm against gold standard care. The null hypothesis states that there is no difference between outcomes in standard clinical care and macusoft software.

The investigators anticipate from previous work that there is deviation from NICE guidelines on a number of occasions. Therefore The investigators suggest an alternative hypothesis that states there the outcomes will show a difference between standard care and outcomes presented from macusoft algorithm software.

Study timetable

The study is estimated to take 9 months, broadly as follows:

• Months 1-6: Research set-up, patient recruitment, data preparation. Collect data on decisions made with and without MacuSense (the algorithm will not be altered during the study)
• Months 7-9: Statistical analysis and validation of observational evidence

Study details:

How the study will operate

The study will operate as follows:

1. Patient recruited and consented when attending clinic for a regular follow-up appointment.

2. Consultant ophthalmologist makes a decision regarding intravitreal treatment interval following current practice.

3. Patient's historical diagnostic data will be analysed by the computer program, MacuSense. This pseudonymiseddata will be able to view by Dr Zakri and the macusoft design team.

4. The consultant ophthalmologists' original decision will be compared to the analysis made with MacuSense. No impact on the clinical care given will be made.

Conditions

Wet Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Interventions

Macusense Assessment Software

Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patients with a diagnosis of wet Age Related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) and/or Retinal Vein Occlusion (RVO), who have already had a course of intravitreal treatment for at least one year.

Exclusion Criteria

• Patients with more than one ophthalmic pathology will be excluded
• A patient will be excluded if, during the first year of treatment, they have needed cataract surgery or vitreoretinal surgery or have developed macular pathology other than wet AMD, DMO or RVO.
• Patients included in other trials during the period the trial is running, will be excluded from eligibility.
• Patients who do not wish to/are unable to consent will be excluded from the trial.
• Patients aged 100 years and over

• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Guy's and St Thomas' NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Guy's and St Thomas's NHS Foundation Trust

London, Westminster, United Kingdom

Countries

United Kingdom

Facility Contacts

Nigel P Davies, PhD

Role: primary

nigel.davies@gstt.nhs.uk

+442071887188 ext. 4321

Other Identifiers

308657

Identifier Type: -

Identifier Source: org_study_id